DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,977 shares of the medical device company’s stock after selling 17,691 shares during the period. Geneva Capital Management LLC’s holdings in DexCom were worth $8,786,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC increased its stake in shares of DexCom by 79.1% in the third quarter. Farther Finance Advisors LLC now owns 2,568 shares of the medical device company’s stock worth $172,000 after buying an additional 1,134 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of DexCom by 14.0% in the third quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock worth $1,463,000 after buying an additional 2,475 shares during the last quarter. National Pension Service increased its stake in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares during the last quarter. Asset Management One Co. Ltd. increased its stake in shares of DexCom by 10.4% in the third quarter. Asset Management One Co. Ltd. now owns 235,474 shares of the medical device company’s stock worth $15,786,000 after buying an additional 22,268 shares during the last quarter. Finally, QRG Capital Management Inc. increased its stake in shares of DexCom by 8.6% in the third quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock worth $1,052,000 after buying an additional 1,248 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM stock opened at $81.96 on Thursday. The company has a market capitalization of $32.03 billion, a P/E ratio of 57.31, a PEG ratio of 2.30 and a beta of 1.14. The company has a 50-day simple moving average of $84.90 and a 200 day simple moving average of $76.94. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.